about
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancersGuidelines for the diagnosis and treatment of malignant pleural mesotheliomamiR-193a-3p is a potential tumor suppressor in malignant pleural mesotheliomaHaemolysis during sample preparation alters microRNA content of plasma.Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.The physiological rationale of heat and moisture exchangers in post-laryngectomy pulmonary rehabilitation: a review.Neoadjuvant strategies for non-small cell lung cancer.Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.Tolerability of gefitinib in patients receiving treatment in everyday clinical practiceFactors associated with survival in a large series of patients with malignant pleural mesothelioma in New South WalesKCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.Chemoprevention in lung carcinogenesis--an overview.The 'grey area' between small cell and non-small cell lung carcinomas. Light and electron microscopy versus clinical data in 14 cases.Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer.Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.Effect of N-acetylcysteïne on Photofrin-induced skin photosensitivity in patients.A new method to determine dose-effect relations for local lung-function changes using correlated SPECT and CT data.Photodynamic therapy: a promising new modality for the treatment of cancer.MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.Clinical practice guidelines for malignant pleural mesothelioma.An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.Circulating microRNAs: Association with disease and potential use as biomarkers.Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma.Molecular biomarkers in malignant mesothelioma: state of the art.The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma.Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review.Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.Validation of tissue microarray technology in malignant pleural mesothelioma.Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.Malignant mesothelioma in Australia 2015: Current incidence and asbestos exposure trends.The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.
P50
Q27824805-CF8FF639-331D-4C4E-9C26-7180D8201B82Q28207228-A5DCC535-4ED5-4B1E-9591-696A9A6A3129Q28207853-7574F5CC-F2BF-4CB6-95F7-62B098B707A2Q28394028-2CF1BE35-526F-406B-B5BA-F6B4CC823908Q28397829-1971923F-1BF2-4A86-9DD8-56905F4F7F76Q34016595-E0F1FDFA-D39D-4DED-98E1-E435A0E8EF20Q34289841-93EDE4A0-8BA0-4394-B75F-0A489C022468Q34431907-DC5850AE-BB0A-47E8-A5EB-0F7A1F0D4000Q34447477-3358AD99-A4E7-4726-B4A3-A4AE490A1C8AQ34714085-DEF93986-BA57-452E-9366-2EC5F82F51C2Q34970431-BFA3C678-1488-4011-8938-8B1898711181Q35111316-9FA59F9C-16E9-4757-AD75-E79F56A99BC5Q35511541-B666352B-6133-4DDE-A51E-969AB7513BB0Q35602194-E6AA0E2C-673C-4527-8705-AD33918FEFB2Q35678085-47796A79-832E-4E4A-8F34-8DE4BFDDB389Q36035319-8F66F575-FEE9-4922-B01B-0F14DC642FBFQ36081391-917A66F4-ED57-44DB-A550-2CC50252F003Q36236331-1907E139-2298-4EBA-A4DA-08BF2AAAE280Q36425271-8CBA77F5-1D30-4EF8-B5B6-35A3572F49B2Q36431122-020895CD-A728-4525-BF5E-0A6F49D176BCQ36614143-60D4D1FC-DACC-4AF5-9635-1F4DDF6C330BQ36648829-8409BD50-A5ED-41EC-83A2-F3C47A9CAAF9Q36662001-6C442340-74F0-4A90-8C2E-07FAA1D7B49AQ36691461-65091EE4-E2D0-4EC6-B26C-BAF17BC30187Q36762884-8B590263-8D02-47AE-ABF5-7EF4C60ECEA2Q36814676-D74CBAC1-42F0-4017-955C-F137358A9C18Q37049227-8FBA0495-BFDD-4F6F-B205-A27E1C3714ABQ37457391-9D2B9E67-0907-4534-822F-44102C6D9FCFQ37507415-1F0DE24C-6306-40B7-BD7E-ECFAFC401B70Q37818867-F9B170ED-5FD7-4359-AE8C-43F1317BAED2Q37832380-69EE3D57-89F8-4AEC-BF21-C62790F77672Q37857610-97C3B7BA-7609-4720-88C6-D354628FDB6BQ37998245-0299E7D7-67DA-4E0F-90C0-8F5F5C97B451Q38061139-402422D1-214A-41D1-8556-90F616118791Q38118298-FA8AA2D4-8209-4E10-A726-1BD012C0598EQ38119922-0584D8F5-F224-4743-BAAA-65E53C618521Q38412580-F03A20D0-05F4-4768-B7EB-986EED339BA4Q38718563-3D04D3F4-599D-4AA2-8789-0D505199F557Q38814688-202FC46C-1762-4475-B1C6-1C48E51CF157Q38978231-CBA35918-CB53-425B-983D-4182A2F47F73
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nico van Zandwijk
@ast
Nico van Zandwijk
@en
Nico van Zandwijk
@es
Nico van Zandwijk
@nl
Nico van Zandwijk
@sl
type
label
Nico van Zandwijk
@ast
Nico van Zandwijk
@en
Nico van Zandwijk
@es
Nico van Zandwijk
@nl
Nico van Zandwijk
@sl
prefLabel
Nico van Zandwijk
@ast
Nico van Zandwijk
@en
Nico van Zandwijk
@es
Nico van Zandwijk
@nl
Nico van Zandwijk
@sl
P1053
E-4177-2012
P106
P1153
55664676800
P21
P2798
P31
P3829
P496
0000-0002-8405-9688